SIShigeki Ito

Shigeki Ito

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shigeki Ito has a total of 206 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnosis and management of acute myeloid leukemia with mutated CEBPA using CEBPA-Trass, a targeted sequencing approach

    by Jun Nakata, Daisuke Motooka, Hiroyuki Yamano, Yuki Takada, Hiroko Nakajima, Fumihiro Fujiki, Soyoko Morimoto, Yoshiki Nakae, Manabu Kawakami, Yuta Katayama, et al.

    Acute myeloid leukemia (AML) with mutated CEBPA (CEBPA-AML) was first recognized as a distinct subtype associated with favorable prognosis in 2002, and its diagnostic criteria and clinical management have been refined over time. However, several challenges remain, including the lack of accurate mutation-based methods for measurable residual disease (MRD) detection. Here, we developed a targeted next-generation sequencing approach for the CEBPA gene, which uses adapter-free PCR amplification of hotspot regions followed by paired-end sequencing to improve analytical performance (termed CEBPA-Trass), and evaluated its clinical performance in samples from the WT1-AM-04 study. CEBPA-Trass successfully detected a cryptic long insertion missed by conventional short-read sequencing. Analytical validation showed higher background for missense variants, whereas insertions or deletions involving three or more base pairs were rarely detected in negative controls and typically below 10⁻⁴, indicating high analytical specificity. Dilution experiments further showed linear detection of insertions or deletions involving three or more base pairs with a limit of detection of 10⁻⁴ -10⁻⁵, comparable to the sensitivity of real-time PCR-based MRD assays, and aligned with the in-frame mutation patterns currently associated with favorable-risk CEBPA-AML. Clinically, CEBPA-Trass-based MRD assessment significantly stratified relapse risk after both first and last consolidation therapy. Specifically, the assessment after last consolidation showed that more than 80% of MRD-positive patients relapsed, whereas more than 80% of MRD-negative patients remained in remission for over two years. These findings suggest that CEBPA-Trass enables accurate mutation-based MRD monitoring and may improve both the diagnosis and risk stratification of patients with CEBPA-AML.

  • Nonlarge, Low Platelet Component Concentration Fraction: A Novel Platelet Component‐Based Screening Marker for Immune Thrombocytopenia

    by Takuya Chiba, Keijiro Suzuki, Akihiro Otsu, Shugo Kowata, Shigeki Ito, Tohru Fujiwara

    Introduction: The use of automated hematology analyzers for immune thrombocytopenia (ITP) screening has traditionally relied on platelet size‐related indices, including mean platelet volume and immature platelet fraction. The ADVIA 2120i Hematology System calculates nine platelet fractions based on platelet volume (Vol) and refractive index (RI), the latter reflecting intracellular component concentration. This study evaluated the nonlarge, low platelet component concentration fraction (NL‐LPLC%) as a potential ITP‐specific marker. Methods: We retrospectively analyzed 55 untreated patients with thrombocytopenia (ITP, 23; myelodysplastic syndromes [MDS], 19; aplastic anemia [AA], 13) and 34 healthy controls. The NL‐LPLC% was measured and compared with the reticulated platelet fraction (RP%) and other platelet indices. Results: Receiver operating characteristic curve analysis revealed that the NL‐LPLC% (RI: < 1.373, Vol: < 20 fL) showed high diagnostic performance for ITP (sensitivity, 91.3%; specificity, 90.6%). In contrast, large, low component platelets (RI: < 1.373, Vol: ≥ 20 fL) showed lower sensitivity (56.5%) and specificity (65.6%). Patients with ITP had a significantly higher RP% than those with MDS and AA ( p < 0.05) but a lower NL‐LPLC% ( p < 0.01). The NL‐LPLC% and RP% showed a strong negative correlation ( r = −0.72, p < 0.01). Conclusion: The NL‐LPLC% derived from the nine platelet fractions obtained using an ADVIA 2120i Hematology System may serve as a novel screening marker for ITP, emphasizing platelet quality rather than size alone.

  • CD206 deficiency aggravates paraquat-induced acute lung injury in mice

    by Masahiro Yamashita, Wataru Yasuno, Miyuki Niisato, Yasushi Kawasaki, Eunsang Kwon, Shigeki Ito, Ichiro Kawada


  • Open Access

    Talquetamab in Japanese patients with relapsed/refractory multiple myeloma in the MonumenTAL-1 study

    by Shigeki Ito, Yoshiaki Kuroda, Kazutaka Sunami, Kosei Matsue, Kazunori Imada, Hideto Tamura, Ei Fujikawa, Hiroshi Yamazaki, Mikihiro Takamoto, Lixia Pei, et al.

    Talquetamab is the first G protein–coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). We report the first efficacy and safety results of talquetamab in Japanese patients enrolled as a separate cohort in the global MonumenTAL-1 study. Between July 2022 and December 2023, 36 patients were enrolled and received 0.4 mg/kg talquetamab weekly. Median follow-up was 13.4 months. The overall response rate was 77.8% (55.6% achieved complete response or better). Median time to first response was 1.2 months. Twelve-month duration of response, progression-free survival, and overall survival rates were 66.4%, 56.3%, and 74.1%, respectively. On-target, off-tumor adverse events (AEs), including taste-, skin- (non-rash), nail-, and rash-related AEs, were common (80.6%, 66.7%, 55.6%, and 36.1%, respectively) and mostly grade 1/2. Cytokine release syndrome occurred in 75.0% of patients; all events were grade 1/2. The rate of infection was 52.8%; the rate of grade 3/4 infection was 16.7% (one led to death [pneumonia]). One patient discontinued talquetamab and three patients died due to AEs. Results were generally consistent with the global MonumenTAL-1 population, demonstrating talquetamab as an important novel treatment for Japanese patients with RRMM. Clinical trial registration number: NCT03399799/NCT04634552.


  • Open Access

    Phase 1 study of talquetamab, a humanized GPRC5D x CD3 bispecific antibody, in Japanese patients with relapsed/refractory MM

    by Shinsuke Iida, Kazutaka Sunami, Shigeki Ito, Junichiro Yuda, Ei Fujikawa, Mikihiro Takamoto, Kensuke Aida, Hiroshi Yamazaki, Marimo Takahashi, Tadao Ishida

    The bispecific antibody talquetamab demonstrated substantial responses in heavily pretreated relapsed or refractory multiple myeloma (RRMM) in the global phase 1/2 MonumenTAL-1 study. This study, evaluated the safety and efficacy of talquetamab in Japanese patients with RRMM pretreated with a proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody. The primary endpoints were frequency and type of treatment-emergent adverse events (TEAEs) and serious AEs including dose-limiting toxicity (DLT). The secondary endpoints were overall response (ORR; partial response or better), duration of, and time to response. At data cutoff, 15 patients had received subcutaneous talquetamab at three doses (Cohort 1: 135 µg/kg weekly [QW, n = 4]; Cohort 2: 400 µg/kg [QW, n = 5]; Cohort 3: 800 µg/kg [Q2W, n = 6]). No DLTs, deaths, or AE-related dose reductions/treatment discontinuation were observed. Common TEAEs were neutropenia (60.0%), lymphopenia (53.3%), and CRS (46.7%). TEAEs of clinical interest (all Grade ≤ 2) were dysgeusia, skin toxicity, nail disorder, and dry mouth. With an overall median follow-up of 9.0 months, the ORR was 60.0% (95% confidence interval 32.3%, 83.7%). Talquetamab showed substantial responses in Japanese patients with RRMM, consistent with the global MonumenTAL-1 study, supporting its potential as a new standard of care for Japanese RRMM patients.


  • Open Access

    Dimethyl Fumarate Suppresses the Proliferation of HTLV-1-infected T Cells by Inhibiting CBM Complex-triggered NF-B Signaling

    by Tsuyoshi Sato, Takahiro Maeta, Shigeki Ito

    Background/Aim: Adult T-cell leukemia (ATL) is a peripheral T-lymphocytic malignancy influenced by human T-cell leukemia virus type 1 (HTLV-1) infection. Aggressive ATL has a poor prognosis, therefore newer agents are desperately needed. We revealed that dimethyl fumarate (DMF) causes ATL cell death via inhibition of nuclear factor-kappa B (NF-B) and signal transducer and activator of transcription 3 signaling. Here, we evaluated the specific mechanism of DMF effects on NF-B signaling in MT-2 HTLV-1-infected T-cells. Materials and Methods: We examined the effects of DMF on the caspase recruitment domain family member 11 (CARD11)–BCL10 immune signaling adaptor (BCL10)–mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) (CBM) complex and upstream signaling molecules which are critical for NF-B signaling in MT-2 cells by immunoblotting. We also explored its effects on cell-cycle distribution. Furthermore, we assessed whether the BCL2 apoptosis regulator (BCL2)/BCL2-like 1 (BCL-xL) inhibitor navitoclax promoted the inhibitory effect of DMF on cell proliferation and apoptosis-associated proteins by trypan blue exclusion test and immunoblotting, respectively. Results: DMF inhibited constitutive phosphorylation of CARD11 followed by suppression of inhibitory-B kinase α/β phosphorylation at serine in a dose-dependent fashion in MT-2 cells. Furthermore, DMF inhibited MALT1 and BCL10 expression in the same fashion. However, DMF did not prevent the phosphorylation of protein kinase C-β, an upstream signaling molecule of CARD11. Cell-cycle analysis highlighted that DMF treatment at 75 μM resulted in the accumulation of cells at the sub-G1 and G2/M phases. Navitoclax modestly promoted DMF-induced suppression of MT-2 cells via inhibition of cellular inhibitor of apoptosis protein-2 expression and c-JUN N-terminal kinase phosphorylation. Conclusion: The suppression of MT-2 cell proliferation by DMF makes its further evaluation as an innovative agent for therapy of ATL worthwhile.


  • Open Access

    Supplementary Tables S1 to S5 and Supplemental Figures 1 to 15 from SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma

    by Mariko Ishibashi, Risa Takahashi, Asako Tsubota, Makoto Sasaki, Hiroshi Handa, Yoichi Imai, Norina Tanaka, Yutaka Tsukune, Sakae Tanosaki, Shigeki Ito, et al.

  • The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma

    by Ryosuke Kinoshita, Mariko Ishibashi, Hiroshi Handa, Makoto Sasaki, Yoichi Imai, Norina Tanaka, Shigeki Ito, Mika Sunakawa-Kii, Yuta Kaito, Toshio Asayama, et al.


  • Hematologic Diseases

    by Hirofumi Sawai, Masaatsu Yagi, Kimihiro Matsumoto, Masahiro Ieko, Satoshi Goto, Shigeki Ito, Daishi Saito

  • Open Access

    Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study

    by Tadao Ishida, Shigeki Ito, Junji Tanaka, Michihiro Uchiyama, Yawara Kawano, Philippe Moreau, Thomas Martin, Marie-Laure Risse, Keisuke Tada, Kenshi Suzuki, et al.